<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806049</url>
  </required_header>
  <id_info>
    <org_study_id>NSGO/AVANOVA-Triplet</org_study_id>
    <nct_id>NCT03806049</nct_id>
  </id_info>
  <brief_title>Trial Comparing Niraparib-bevacizumab-TSR042 and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer</brief_title>
  <official_title>ENGOT-OV42-NSGO/AVANOVA-Triplet: A Randomized Study to Evaluate the Efficacy of Niraparib-bevacizumab-TSR042 Triplet Against Niraparib-bevacizumab Doublet and Against Standard of Care in Women With Platinum-sensitive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society for Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Society of Gynaecological Oncology - Clinical Trials Unit</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NSGO / AVANOVA-Triplet: This three-arm randomized trial is to demonstrate efficacy of
      niraparib-bevacizumab-TSR-042 triplet combination against standard of care treatment and to
      demonstrate efficacy of niraparib-bevacizumab-TSR-042 triplet combination against
      niraparib-bevacizumab doublet combination for patients with platinum-sensitive epithelial
      ovarian, fallopian tube, or peritoneal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized open-label trial to compare two different chemotherapy-free
      arms against standard of care treatment in patients with recurrent ovarian cancer with &gt;6
      months of chemotherapy-free interval to prior therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, open-label, three arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>42 months</time_frame>
    <description>the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST v1.1 or death by any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in Sub-Population in months</measure>
    <time_frame>42 months</time_frame>
    <description>the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST v1.1 or death by any cause, whichever occurs first for the predefined study subgroups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">337</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>A: triplet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy-free combination of niraprib + bevacizumab + TSR042</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Doublet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy-free combination of niraparib + bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care chemotherapy: Carboplatin + paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>given orally once daily</description>
    <arm_group_label>A: triplet</arm_group_label>
    <arm_group_label>B: Doublet</arm_group_label>
    <other_name>Zejula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>given as iv infusion every three weeks</description>
    <arm_group_label>A: triplet</arm_group_label>
    <arm_group_label>B: Doublet</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR042</intervention_name>
    <description>Given as IV infusion every three weeks</description>
    <arm_group_label>A: triplet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>given as iv infusion every three weeks</description>
    <arm_group_label>C: standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>given as iv infusion every three weeks</description>
    <arm_group_label>C: standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
             (platinum sensitivity defined as no recurrence within 6 months of last receipt of
             platinum/chemotherapy).

          2. High-grade serious or high-grade endometrioid histology or any histology with known
             BRCA mutation.

          3. Patient consents to perform BRCA test, and PD-L1 expression.

          4. Prior line of therapy: Patients must have received platinum-containing therapy for
             primary disease.

          5. No limits on number of platinum-based therapies.

          6. Up to one non-platinum-based line of therapy in recurrent setting is allowed.

          7. Patients may have received bevacizumab (or other anti-VEGF therapy) prior to entering
             in the trial.

          8. Patients may have participated in a PARP inhibitor maintenance trial or have received
             maintenance PARP inhibitor therapy are allowed, though it is necessary to unblind
             patient in order to correctly stratify. Patients who received a PARP inhibitor as
             definitive are not eligible. Patients may have participated in a trial containing
             immune-checkpoint inhibitor.

          9. Target group: Age 18+

         10. Histological confirmed ovarian, fallopian tube or peritoneal cancers

         11. Patients must give informed consent

         12. Patients may have undergone primary or interval debulking surgery

         13. Patients may have received bevacizumab or other anti-angiogenic therapy

         14. Patients may have received a PARP inhibitor as first-line maintenance therapy.

         15. Patients must have disease that is measurable according to RECIST or assessable
             according to the GCIG criteria

         16. The patient agrees to complete PROs (QoL questionnaire) during study treatment AND at
             one additional time point 8 weeks following progression of disease

         17. ECOG performance status 0-2

         18. Adequate organ function

               1. Absolute neutrophil count (ANC) ≥1,5 x 109/L

               2. Platelets &gt;100 x 109/L

               3. Hemoglobin ≥ 9g/dl

               4. Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine
                  clearance ≥50mL/min using Cockcroft-Gault formula

               5. Total bilirubin ≤1.5x ULN

               6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN
                  unless liver metastases are present, in which case they must be ≤5x ULN.

         19. Able to take oral medications

         20. Life expectancy of at least 12 weeks

         21. Patients must fulfill all inclusions criteria and according to investigator fit to
             receive niraparib, bevacizumab and TSR042.

         22. Women of childbearing potential must use adequate birth control for the duration of
             study participation -

        Exclusion Criteria:

        Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial
        cancers and cancer types not mentioned in the inclusion criteria 2. Concurrent cancer
        therapy 3. Concurrent treatment with an investigational agent or participation in another
        clinical trial 4. Major injuries or surgery within the past 21 days prior to start of study
        treatment with incomplete wound healing and/or planned surgery during the on-treatment
        study period 5. Previous malignant disease: patients are not eligible for the study if
        diagnosis, detection or treatment of invasive cancer (other than ovarian cancer; with the
        exception of basal or squamous cell carcinoma of the skin that was definitively treated)
        was detected within 2 years prior to randomization 6. Active infections or other serious
        underlying significant medical illness, abnormal laboratory finding or psychiatric
        illness/social situation that would, in the Investigator's judgment, makes the patient
        inappropriate for this study 7. Gastrointestinal disorders or abnormalities that would
        interfere with absorption of the study drug 8. History of bowel obstruction, including
        sub-occlusive disease, related to the underlying disease and history of abdominal fistula,
        gastrointestinal perforation or intra-abdominal abscess. Evidence of recto-sigmoid
        involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of
        bowel obstruction 9. Known contraindications to PARP inhibitors, VEGF directed therapy or
        immune checkpoint inhibitors 10. Known uncontrolled hypersensitivity to the investigational
        drugs 11. History of major thromboembolic event defined as:

          -  Uncontrolled pulmonary embolism (PE)

          -  Deep venous thrombosis (DVT)

          -  Other related conditions, though patients with stable therapeutic anticoagulation for
             more than three months prior randomization are eligible for this study. This also
             apply to PE &amp; DVT.

             12. History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             hemorrhage within the past 3 months 13. History of clinically significant hemorrhage
             in the past 3 months 14. Uncontrolled and/or symptomatic CNS metastasis or
             leptomeningeal carcinomatosis (Dexamethasone/prednisone therapy will be allowed if
             administered as stable dose for at least one month prior randomization) 15.
             Significant cardiovascular diseases, including uncontrolled hypertension, clinically
             relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months
             prior to randomization, congestive heart failure &gt; NYHA III, severe peripheral
             vascular disease, QT prolongation &gt;470 msec ,clinically significant pericardial
             effusion 16. Pregnancy or breastfeeding. Patients with preserved reproductive
             capacity, unwilling to use a medically acceptable method of contraception for the
             duration of the trial and for 3 months afterwards.

             17. Radiographic evidence of cavitation or necrotic tumors with invasion of adjacent
             major blood vessels 18. Active or chronic hepatitis C and/or B infection 19.
             Persistence of clinically relevant therapy related toxicity from previous chemotherapy
             20. Proteinuria as demonstrated by: (a) urine protein: creatinine (UPC) ratio &gt;/= 1.0
             at screening OR (b) urine dipstick for proteinuria &gt;/=2+ (patients discovered to have
             &gt;/=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hr urine
             collection and must demonstrate &lt;/=1g of protein in24 hours to be eligible 21.
             Patients must not have any known history of MDS 22. Patients must not have known
             persistent (&gt; 4 weeks) ≥ Grade 2 hematological toxicity from prior cancer therapy 23.
             Patients must not have known ≥ Grade 3 thrombocytopenia or anemia with the last
             chemotherapy regimen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANSOOR RAZA R MIRZA</last_name>
    <role>Study Chair</role>
    <affiliation>NSGO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mansoor R Mirza, MD</last_name>
    <phone>35459624</phone>
    <email>mansoor@rh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NSGO</name>
      <address>
        <city>Copenhagen</city>
        <state>Sjaelland</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Sjaelland</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <state>Sjaelland</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Haukeland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 13, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy-free regimen</keyword>
  <keyword>niraparib</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>TSR042</keyword>
  <keyword>recurrent ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All individual participant data will be anonymized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

